The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterization of enhancer of zeste homolog 2 (EZH2) expression, activity, and association with the tumor immune microenvironment in olfactory neuroblastoma (ONB).
 
Elisabetta Xue
Honoraria - Emcure
 
Harris Benjamin Krause
Employment - Caris Life Sciences
 
Andrew Elliott
Employment - Caris Life Sciences
 
Ranee Mehra
Stock and Other Ownership Interests - GlaxoSmithKline (I)
Consulting or Advisory Role - Coherus Biosciences; Janssen Oncology; Merck KGaA
Research Funding - AstraZeneca; Merck
Travel, Accommodations, Expenses - Merck KGaA
(OPTIONAL) Uncompensated Relationships - AstraZeneca
 
Vaia Florou
Consulting or Advisory Role - Deciphera; Incyte
 
Chul Kim
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Daiichi Sankyo; Eisai; Janssen; Jazz Pharmaceuticals; Regeneron; Sanofi
Research Funding - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Janssen; Karyopharm Therapeutics; Lyell Immunopharma; Novartis; Regeneron
 
Heloisa P. Soares
Honoraria - TM Isotope Technologies Munich SE
Consulting or Advisory Role - AstraZeneca; Ipsen; Novartis; Pfizer; TerSera
(OPTIONAL) Uncompensated Relationships - Healing NET Foundation; NCCN; North American Neuroendocrine Tumor Society
 
Emil Lou
Honoraria - Boston Scientific; Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline; Novocure
Consulting or Advisory Role - Boston Scientific; Novocure; Novocure; Novocure; Novocure
Research Funding - Intima; Novocure
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Minnetronix Medical; NomoCan
 
Ari M. Vanderwalde
Employment - Caris Life Sciences
Consulting or Advisory Role - George Clincal; West Clinic
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Immunomedics/Gilead (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Replimune (Inst)
 
David Spetzler
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Caris Life Sciences
Research Funding - Caris Life Sciences
Patents, Royalties, Other Intellectual Property - Caris Life Sciences holds and has pending patents with intellectual property interests relating to health and medicine.
Travel, Accommodations, Expenses - Caris Life Sciences
 
Dara Mark Bracken-Clarke
(OPTIONAL) Uncompensated Relationships - LEO Pharma
 
Nyall R London
Research Funding - Merck
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); ImmunityBio (Inst); Incyte (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Marengo Therapeutics (Inst); Merck (Inst); NextCure (Inst); PDS Biotechnology (Inst); Pfizer (Inst); Precigen (Inst); Syndax (Inst); Syntrix Biosystems (Inst)
Patents, Royalties, Other Intellectual Property - COMBINATION PDL1 AND TGF-BETA BLOCKADE IN PATIENTS WITH HPV+ MALIGNANCIES Publication number: 20200062849 Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subje
 
Charalampos S. Floudas
No Relationships to Disclose